These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 23815950)

  • 1. Hemophilia A in the third millennium.
    Franchini M; Mannucci PM
    Blood Rev; 2013 Jul; 27(4):179-84. PubMed ID: 23815950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor VIII therapy for hemophilia A: current and future issues.
    Aledort L; Ljung R; Mann K; Pipe S
    Expert Rev Hematol; 2014 Jun; 7(3):373-85. PubMed ID: 24717090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnosis and management of congenital hemophilia.
    Carcao MD
    Semin Thromb Hemost; 2012 Oct; 38(7):727-34. PubMed ID: 23011791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemophilia. Strategies for the treatment of inhibitor patients.
    Ingerslev J
    Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapy of haemophilia A.
    Gringeri A; Muça-Perja M; Mangiafico L; von Mackensen S
    Expert Opin Biol Ther; 2011 Aug; 11(8):1039-53. PubMed ID: 21682657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G; Spranger T; Brackmann HH
    Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia.
    Schaub RG
    Biochem Pharmacol; 2011 Jul; 82(2):91-8. PubMed ID: 21453683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging Issues in Diagnosis, Biology, and Inhibitor Risk in Mild Hemophilia A.
    Castaman G; Eckhardt C; van Velzen A; Linari S; Fijnvandraat K
    Semin Thromb Hemost; 2016 Jul; 42(5):507-12. PubMed ID: 27148839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desmopressin in mild hemophilia A: indications, limitations, efficacy, and safety.
    Lethagen S
    Semin Thromb Hemost; 2003 Feb; 29(1):101-6. PubMed ID: 12640572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia a and inhibitors.
    d'Oiron R; Volot F; Reynaud J; Peerlinck K; Goudemand J; Guérois C; Rothschild C; Chambost H; Borel-Derlon A; Roussel-Robert V; Marquès-Verdier A; Lienhart A; Berthier AM; Moreau P; Lambert T;
    Semin Hematol; 2006 Jan; 43(1 Suppl 1):S3-9. PubMed ID: 16427382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Turoctocog alfa for the treatment of hemophilia a.
    Vakil NH; Fujinami N; Martin-Stone S
    Pharmacotherapy; 2014 Oct; 34(10):1091-101. PubMed ID: 25052207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Turoctocog alfa for the treatment of hemophilia A.
    Haddley K
    Drugs Today (Barc); 2014 Feb; 50(2):121-31. PubMed ID: 24619589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recognition of hemophilia A in an elderly patient.
    Cáceres W; McCurdy S
    Bol Asoc Med P R; 1998; 90(4-6):85-7. PubMed ID: 9866274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P; Plamenová I; Hollý P; Stasko J
    Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Revision consensus hemophilia: treatment and responsibility. Nederlandse Vereniging van Hemophilia Patients].
    Briët E; Mauser-Bunschoten EP
    Ned Tijdschr Geneeskd; 1997 Dec; 141(52):2566-71. PubMed ID: 9555158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A.
    Díaz-Ricart M; Isola IM; Escolar G
    Drugs Today (Barc); 2018 Oct; 54(10):591-600. PubMed ID: 30398480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular genetics of hemophilia A].
    De Brasi CD; Slavutsky IR; Larripa IB
    Medicina (B Aires); 1996; 56(5 Pt 1):509-17. PubMed ID: 9239887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New protocol for immune tolerance induction in acquired hemophilia.
    Nemes L; Pitlik E
    Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges.
    Coppola A; Tagliaferri A; Di Capua M; Franchini M
    Semin Thromb Hemost; 2012 Feb; 38(1):79-94. PubMed ID: 22314606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.